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Summary
 
Autoantibodies and immune complexes are major pathogenic factors in autoimmune injury,
responsible for initiation of the inflammatory cascade and its resulting tissue damage. This acti-
vation results from the interaction of immunoglobulin (Ig)G Fc receptors containing an activa-
tion motif (ITAM) with immune complexes (ICs) and cytotoxic autoantibodies which initiates
and propagates an inflammatory response. In vitro, this pathway can be interrupted by coliga-
tion to Fc
 
g
 
RIIB, an IgG Fc receptor containing an inhibitory motif (ITIM). In this report, we
describe the in vivo consequences of Fc
 
g
 
RII deficiency in the inflammatory response using a
mouse model of IC alveolitis. At subthreshold concentrations of ICs that fail to elicit inflamma-
tory responses in wild-type mice, Fc
 
g
 
RII-deficient mice developed robust inflammatory re-
sponses characterized by increased hemorrhage, edema, and neutrophil infiltration. Bronchoal-
veolar fluids from Fc
 
g
 
RII
 
2
 
/
 
2
 
 stimulated mice contain higher levels of tumor necrosis factor
and chemotactic activity, suggesting that Fc
 
g
 
RII deficiency lowers the threshold of IC stimula-
tion of resident cells such as the alveolar macrophage. In contrast, complement- and comple-
ment receptor–deficient mice develop normal inflammatory responses to suprathreshold levels
of ICs, while FcR
 
g
 
2
 
/
 
2
 
 mice are completely protected from inflammatory injury. An inhibitory
role for Fc
 
g
 
RII on macrophages is demonstrated by analysis of Fc
 
g
 
RII
 
2
 
/
 
2
 
 macrophages which
show greater phagocytic and calcium flux responses upon Fc
 
g
 
RIII engagement. These data re-
veal contrasting roles for the cellular receptors for IgG on inflammatory cells, providing a regu-
latory mechanism for setting thresholds for IC sensitivity based on the ratio of ITIM to ITAM
Fc
 
g
 
R expression. Exploiting the Fc
 
g
 
RII inhibitory pathway could thus provide a new thera-
peutic approach for modulating antibody-triggered inflammation.
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I
 
mmune complex (IC)
 
1
 
-induced inflammatory responses
are significant contributors to the pathogenic mecha-
nisms responsible for tissue destruction in a number of au-
toimmune conditions. The initiation of this inflammatory
response by IgG-containing ICs may be triggered by either
of two pathways: the soluble proteins of the complement
system, or the cellular receptors for IgG, the Fc receptors
(1). The binding of the complement component C1q to
the IC leads to a cascade of proteolytic activation steps in-
cluding the subsequent binding and proteolytic activation
of C4 and C2 to form the C4bC2b complex or C3 conver-
tase. The critical step of proteolytic conversion of C3 to
C3b may lead subsequently to the activation of the late
complement components C5–9 and the generation of sev-
eral proinflammatory molecules, including the lytic mem-
brane attack complex, the chemoattractants C5a and C3a,
and independently lead to the interaction with the cellular
receptors for C3 (2). Since these highly inflammatory mol-
ecules are found activated in inflammatory states, a direct
causal relationship between complement activation and IC
injury has often been assumed. However, the study of IC
injury in mouse strains deficient in complement compo-
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; HSA,
human serum albumin; IC, immune complex; ITAM, immunoreceptor
tyrosine-based activation motif; ITIM, immunoreceptor tyrosine-based
inhibition motif; MIP, macrophage-inflammatory protein; MPO, my-
eloperoxidase. 
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nents and in the cellular receptors for IgG has allowed a
systematic evaluation of these individual inflammatory
pathways. Studies in FcR-deficient or complement-defi-
cient mice have demonstrated the dominant role of the
FcR pathway in initiating autoimmune injury. Thus, IC-
induced inflammation in the skin, as modeled by the
Arthus reaction, is dependent on FcR and not complement
activation (3, 4). Similarly, the activation of FcRs is re-
quired for IC-triggered glomerulonephritis in a murine
model of systemic lupus (5). Taken together, these data ar-
gue for a prominent role for FcR engagement rather than
complement in IgG-triggered systemic autoimmunity in a
wide variety of tissue sites.
In the mouse, IgG-containing ICs may interact with one
of three cellular IgG receptors, two of which, Fc
 
g
 
RI and
Fc
 
g
 
RIII, lead to cellular activation and are multimeric re-
ceptors containing both a ligand-binding subunit and the
associated signaling subunit, the immunoreceptor tyrosine-
based activation motif (ITAM)-containing 
 
g
 
 chain (6–11).
The third receptor for IgG, Fc
 
g
 
RII, is a single subunit re-
ceptor, and its immunoreceptor tyrosine-based inhibitory
motif (ITIM)-containing cytoplasmic domain (12–14) in-
hibits ITAM-mediated cellular activation signals through
the recruitment of the inositol phosphatase SHIP (15).
Coligation of Fc
 
g
 
RII and an ITAM-containing receptor
leads to aborted Fc
 
e
 
RI and Fc
 
g
 
RIII-triggered activation in
mast cells (16, 17) and B cell receptor–triggered activation
in B cells (18–20). Fc
 
g
 
RII is widely expressed on all he-
matopoietic lineage cells, including monocytes and granu-
locytes, raising the possibility that this receptor may func-
tion to modulate IC-triggered inflammatory responses in
vivo
 
 
 
by determining thresholds for activation of inflamma-
tory cells. The present study was undertaken to investigate
this possibility in an in vivo murine model of IC-triggered
alveolitis. In this passive model of acute IC disease, the an-
tigen OVA is injected intravenously followed by the deliv-
ery of specific anti-OVA IgG to the airways by intratra-
cheal administration. ICs are formed in situ in the lung and
incite an acute inflammatory response within 4 h. The resi-
dent alveolar macrophage is the dominant cell type present
in the alveolar spaces and is therefore a likely contributor to
the initiation of the IC-triggered inflammatory cascade,
elaborating a number of cytokines, including IL-1 (21–23),
TNF-
 
a
 
 (24, 25), IL-6 (26), and platelet-activating factor
(PAF [23, 27]), that act in both a paracrine and autocrine
manner. The production of chemokines, including mac-
rophage-inflammatory protein (MIP)-1 (28), MIP-2, cy-
tokine-induced neutrophil chemoattractant 1 (CINC-1
[29]), IL-8 (30), and C5a (31–33), result in the recruitment
of other inflammatory cell types, predominantly the neu-
trophil, to the lung (for a review, see reference 34). Pro-
duction of vasoactive substances and vascular injury (35) re-
sult in both hemorrhage and edema. This response is
highlighted histologically by hemorrhage, neutrophil infil-
tration, and perivascular edema.
Fc
 
g
 
RII-deficient mice develop augmented inflammatory
responses in IC alveolitis with increased hemorrhage,
edema, and neutrophil infiltration, whereas 
 
g
 
 chain–defi-
 
cient mice are protected. C3-deficient and C5aR–deficient
mice reveal wild-type responses to IC-induced inflamma-
tion. The cell type likely to play a major role in the devel-
opment of alveolitis, the alveolar macrophage, was shown
to have enhanced phagocytic capacity and enhanced cal-
cium influx in response to ICs when lacking Fc
 
g
 
RII.
These results demonstrate the roles of the two opposing
Fc
 
g
 
R systems in the inflammatory response and suggest al-
ternative immunotherapeutic approaches in the treatment
of IC disease.
 
Materials and Methods
 
Mice.
 
Wild-type,
 
 
 
g
 
2
 
/
 
2
 
,
 
 
 
and FcRII
 
2
 
/
 
2
 
 mice were on a
BALB/c background. The C3
 
2
 
/
 
2
 
 mice were a gift of Mike Car-
roll (Harvard University School of Medicine, Boston, MA), and
the C5aR
 
2
 
/
 
2
 
 mice were a gift of Craig Gerard (Children’s Hos-
pital, Boston, MA). All of the mice were bred and housed at
Taconic Farms and used at the age of 6–12 wk.
 
Lung Reverse Passive Arthus Reaction.
 
The reverse passive Ar-
thus reaction was initiated by the intravenous injection of the tail
vein with OVA (Sigma Chemical Co.) 20 
 
m
 
g/g in 200 
 
m
 
l PBS
solution. The mice were anesthetized by inhalation of Metofane
and subsequently injected intratracheally with 60 
 
m
 
l of PBS con-
taining either 30 or 300 
 
m
 
g of rabbit anti–chicken egg albumin
IgG (ICN Pharmaceuticals, Inc.) or PBS alone. After 4 h the
mice were killed, and either a bronchoalveolar lavage (BAL) was
performed with 1 ml of PBS three times per mouse, or the lungs
were removed for formalin fixation or myeloperoxidase (MPO)
assay.
 
Quantitation of Edema and Hemorrhage.
 
Edema was assessed by
a vasopermeability index in mice that received 200 
 
m
 
l of 2%
Evan’s blue dye (Sigma Chemical Co.) in PBS intravenously.
The vasopermeability index is the ratio of the OD
 
630
 
 of the
pooled 3 ml BAL to a 1:20 dilution of serum, and represents the
extravasation of protein-bound Evan’s blue dye into the bron-
choalveolar space.
The amount of alveolar hemorrhage was calculated by multi-
plying the total cell count by the percentage of RBCs determined
by manual differentials of Wright-Giemsa–stained cytospin BAL
samples.
 
Quantitation of Neutrophil Infiltration.
 
Total lung neutrophil ac-
tivity was assessed by MPO assay. After three freeze–thaw cycles,
lungs were homogenized (Polytron homogenizer; Tekmar Co.)
four times for 10 s at a setting of 4, in 10 vol of ice-cold buffer
(50 mM potassium phosphate, pH 7.4). After centrifugation at
25,000 
 
g
 
 for 20 min, the pellet was resuspended in 10 vol of lysis
buffer (50 mM potassium phosphate, pH 6.0, 0.5% HTAB, 10 mM
EDTA), homogenized, freeze–thawed, and sonicated for 15 s. 50
 
m
 
l lysate samples were added to 450 
 
m
 
l of reaction buffer (50 mM
potassium phosphate, pH 6.0, containing 0.167 mg/ml 
 
O
 
-diani-
sidine dihydrochloride and 0.005% H
 
2
 
O
 
2
 
). MPO activity in su-
pernatants was assayed by measuring the change (per minute) in
absorbance at 460 nm resulting from decomposition of H
 
2
 
O
 
2
 
.
 
TNF Assay.
 
Levels of soluble murine TNF-
 
a
 
 
 
were mea-
sured, in duplicate, in appropriately diluted samples of BAL. The
TNF-
 
a
 
 concentration was determined with a mouse TNF-
 
a
 
ELISA kit as described in the manufacturer’s instructions (Gen-
zyme Corp.) and compared with a standard curve.
 
Cell Preparation and Chemotaxis Assay.
 
BALB/c wild-type
mouse bone marrow 0.75 
 
3 
 
10
 
6
 
 cells in 100 
 
m
 
l RPMI 1640 me-
dium, 0.25% human serum albumin (HSA) were added to the 
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Figure 1. IC alveolitis in wild-type
(WT),  g2/2,  C32/2, and C5aR2/2 mice.
(Top panels) Hematoxylin and eosin–
stained formalin-fixed lung sections (origi-
nal magnification: 3200). (Bottom panels)
Wright-Giemsa stains of cytospin prepara-
tions of bronchoalveolar fluid samples. Mice
received OVA intravenously, followed by
300  mg anti-OVA intratracheally.
 
top chamber of a 6.5-mm diameter, 3-
 
m
 
m pore polycarbonate
Transwell culture insert (Costar Corp.) and incubated for 1.5 h
with either RPMI/0.25% HSA or BAL diluted 1:2 in RPMI/
0.25% HSA. The neutrophils that transmigrated into the lower
chamber were vigorously suspended and counted with a FAC-
Scan
 
®
 
 (Becton Dickinson) for 20 s at 60 
 
m
 
l/min with gating on
forward and side scatter.
 
Phagocytosis Assays.
 
Adherent peritoneal macrophages were
obtained from mice after flushing the abdominal cavity with ice-
cold PBS/1% BSA. IgG2b-opsonized SRBCs were prepared as
described previously (11). In brief, TNP-derivitized SRBCs
were extensively washed and incubated with subagglutinating
quantities of culture supernatants of the IgG2b producing anti-
DNP hybridoma U12.5 (a gift of Jay Unkeless, Mount Sinai
Medical Center, New York). After washing away free antibody,
IgG2b-opsonized RBCs were added to adherent macrophages
for 1 h at 37
 
8
 
C. Unphagocytosed RBCs were removed by os-
motic lysis, and phagocytosis plates were fixed with PBS/0.25%
glutaraldehyde before microscopic examination.
 
Calcium Flux Measurements.
 
Peritoneal macrophages were sus-
pended at a concentration of 2 
 
3 
 
10
 
6
 
 cells/ml in DMEM with
10% HI-FCS, 2 
 
m
 
M fura-2/AM (Molecular Probes, Inc.) for 30
min at 35
 
8
 
C. Fura-2/AM–loaded cells were incubated with mAb
2.4G2 (5 
 
m
 
g/ml) for 30 min at 4
 
8
 
C. Cells were stimulated with
goat anti–rat IgG mAb (Cappel) at 25 ng/ml. Relative fluores-
cence was monitored in a Perkin-Elmer fluorimeter.
 
Results
 
Previous studies on the FcR dependence and comple-
ment independence of IC-triggered inflammation were
based on studies using models involving the skin and kid-
ney (3–5, 36, 37). It has been suggested that IC-induced
inflammation in the lung may display a greater dependence
on complement activation pathways than other anatomic
sites (32, 38). To delineate the relative contributions of
complement- and FcR-triggered activation pathways in IC
alveolitis, the inflammatory reactions of wild-type, C3-
deficient, and C5aR-deficient mice were compared. Mice
were killed 4 h after challenge, and lungs were processed
for either histological or quantitative assessment of inflam-
mation. Quantitative analysis included RBC counts of
BAL fluid for an index of hemorrhage; measurement of
Evan’s blue dye extravasation into bronchoalveolar fluid for
edema evaluation; and MPO assay of whole lung tissue as
an indicator of neutrophil infiltration. Wild-type, C3
 
2
 
/
 
2
 
,
C5aR
 
2
 
/
 
2
 
, and FcR 
 
g
 
2
 
/
 
2
 
 mice challenged with 300 
 
m
 
g
rabbit anti-OVA IgG alone had little or no inflammatory
reaction observable histologically or by quantitative assess-
ment of hemorrhage, edema, or neutrophil infiltration (see
Fig. 2, and data not shown). Wild-type mice treated with
both intravenous OVA and 300 
 
m
 
g of anti-OVA to induce
in situ formation of ICs developed robust inflammatory re-
sponses characterized by alveolar hemorrhage, neutrophil
infiltration, and perivascular edema (Figs. 1 and 2). Con-
trary to the conclusion of a prior report that C5aR defi-
ciency significantly attenuated inflammation in this model
(32, 38), we observed minimally reduced inflammatory re-
sponses in IC-treated complement-deficient animals both
qualitatively and quantitatively (Figs. 1 and 2). Histological
analysis revealed that complement-deficient mice exhibited
minimally attenuated hemorrhage with somewhat fewer
RBCs and PMNs seen in BAL specimens (Fig. 1). Quanti-
tative assessment revealed lowered edematous responses,
but no statistically significant differences in BAL RBC
counts or total lung MPO activity were detectable between
wild-type and complement-deficient animals (Fig. 2). In
contrast to the lack of protection in C3- and C5aR-defi-
cient mice, protection in FcR 
 
g
 
2
 
/
 
2
 
 mice was complete.
Alveolar hemorrhage is easily seen in wild-type, C3
 
2
 
/
 
2
 
,
and C5aR
 
2
 
/
 
2
 
 mice but not in 
 
g
 
2
 
/
 
2
 
 mice (Fig. 1 A, top
panels). BAL fluids (Fig. 1, bottom panels) reveal that the
airways of wild-type, C3
 
2
 
/
 
2, and C5aR2/2 mice are filled
with RBCs and recruited neutrophils, but that the airways
of g 2/2 mice show little signs of inflammation and BAL
specimens contain resident alveolar macrophages and few
RBCs and few neutrophils. These data demonstrate that
IC-triggered inflammation in the lung is FcR dependent,
as has been observed in the skin and kidney, and establish
the general importance of the FcR g activation pathway, as
opposed to complement, in IC injury regardless of tissue
site.
Since FcgRII is able to inhibit activation responses gen-
erated by the g chain–associated receptors, FcgRI and III
in vitro, we next set out to determine the in vivo relevance
of this inhibitory pathway in IC-triggered inflammation.
To evaluate the role of FcgRII in the acute inflammatory
response in this FcR-dependent model, wild-type and182 Activation and Inhibitory Fc Receptors In Vivo
FcgRII2/2 mice were challenged with a low dose of poly-
clonal anti-OVA rabbit IgG (30 mg) either in the presence
or absence of intravenously injected OVA. Both wild-type
and FcgRII2/2 mice challenged with rabbit anti-OVA IgG
alone had little or no inflammatory reaction observable his-
tologically (data not shown) or by quantitative assessment
of hemorrhage, edema, or neutrophil infiltration. Similarly,
at these low doses of antibody, wild-type mice challenged
with both OVA and rabbit anti-OVA IgG had little ob-
servable inflammatory responses (Fig. 3, left). However, the
inflammatory response of FcgRII2/2 mice was enhanced,
with increased responses of all three parameters of inflam-
mation (Fig. 3, right; and Fig. 4). Histological changes
noted in FcgRII2/2 mice included enhanced alveolar hem-
orrhage, increased interstitial neutrophil infiltration, and
perivascular edema. These results indicate that FcgRII
functions to set the threshold level for IC-triggered inflam-
mation, which is relieved upon deletion of this gene.
The enhanced infiltration of neutrophils seen in IC-
stimulated lungs of FcgRII2/2 mice suggested that the lo-
cal production of recruitment factors that include inflam-
matory cytokines and chemokines might be enhanced in
the lungs of FcgRII2/2 mice. Indeed, the level of TNF-a
production in BAL fluid is enhanced twofold in FcgRII2/2
mice (Fig. 5 A). Furthermore, FcgRII2/2 BAL fluid con-
tains more than twofold increased neutrophil chemotactic
activity compared with control BAL fluid from wild-type
stimulated lungs (Fig. 5 B). On the other hand, FcgRII2/2,
g2/2, and wild-type neutrophils show equivalent migratory
responses when exposed to chemokine-containing BAL
fluid obtained from IC-stimulated wild-type mice (not
shown). These data are consistent with the hypothesis that
the enhanced neutrophil infiltrative responses seen in
FcgRII2/2 mice is the result of a lower threshold of IC-
triggered activation of FcgR-bearing resident cells, includ-
ing the alveolar macrophage. This activation of resident
cells leads to the increased local production of secondary
Figure 2. IC alveolitis: quanti-
tative assessment of edema, neu-
trophilic infiltration, and hemor-
rhage in wild-type (WT), g2/2,
C32/2, and C5aR2/2 mice. (Top)
Vasopermeability index, as as-
sessed by Evan’s blue dye ex-
travasation into the bronchoalve-
olar space. (Middle) Neutrophilic
infiltration, as assessed by neutro-
phil-specific MPO assay. MPO
activity in lung lysates was mea-
sured at OD450. (Bottom) Alveolar
hemorrhage, as measured by total
RBC counts of BAL. Mice re-
ceived OVA (IC, black bars) or
PBS (Ab, white bars) intrave-
nously, followed by 300 mg
anti-OVA intratracheally. Exper-
imental groups included three to
seven mice per group. PBS con-
trols were not performed for all
genotypes. Data are presented as
mean 6 SEM. The P values
for edematous, neutrophilic, and
hemorrhagic responses were as
follows: 0.02, 0.01, and 0.03, g2/2
vs. wild-type; 0.03, 0.08, and
0.05, C32/2 vs. wild-type; and
0.08, 0.45, and 0.09, C5aR2/2
vs. wild-type, respectively. Statis-
tical analysis was performed with
an unpaired two-tailed Student’s
t test.
Figure 3. IC alveolitis in wild-type (WT) and FcgRII2/2 mice. (Top
panels) Hematoxylin and eosin–stained formalin-fixed lung sections (orig-
inal magnification: 3200). (Bottom panels) Wright-Giemsa stains of
cytospin preparations of bronchoalveolar fluid samples. Mice received
OVA intravenously, followed by 30 mg anti-OVA intratracheally.
Figure 4. IC alveolitis: quantita-
tive assessment of edema, neutro-
philic infiltration, and hemorrhage
in wild-type (WT) and FcgRII2/2
mice. (Top) Vasopermeability index,
as assessed by dye extravasation into
the bronchoalveolar space. (Middle)
Neutrophilic infiltration, as assessed
by neutrophil-specific MPO assay.
MPO activity in lung lysates was
measured at OD450. (Bottom) Alveo-
lar hemorrhage, as measured by total
RBC counts of BAL. Mice received
OVA (IC, black bars) or PBS (Ab,
white bars) intravenously, followed
by 30 mg anti-OVA intratracheally.
Experimental groups included four
to seven mice per group. Data are
presented as mean 6 SEM. The P
values for IC-stimulated edematous,
neutrophilic, and hemorrhagic re-
sponses were 0.03, 0.05, and 0.002,
FcgRII2/2 vs. wild-type, respec-
tively. Statistical analysis was per-
formed with an unpaired two-tailed
Student’s t test.183 Clynes et al.
mediators of inflammation, including TNF-a and chemo-
kines, leading to enhanced recruitment of circulating neu-
trophils.
In the unstimulated state, the normal cellular population
of the alveolar air spaces is dominated by the alveolar mac-
rophage. FACS® analysis of isolated alveolar macrophages
stained with the RII/RIII-specific mAb, 2.4G2, from
wild-type, RII-deficient, and g chain–deficient mice dem-
onstrated high levels of staining, indicating that both
FcgRII and III are expressed on these cells (data not
shown). To further investigate the function of macrophage-
expressed FcgRII in vitro, resting peritoneal macrophages
were isolated from wild-type and FcgRII2/2 mice and
subjected to FcgR cross-linking assays. To assess the early
membrane events associated with combined FcgRII and III
cross-linking, resident macrophages were treated with the
rat mAb 2.4G2 and a secondary goat anti–rat IgG F(ab9)2.
It has been previously shown that g chain–deficient mac-
rophages have abrogated calcium fluxes upon FcgRII/III
cross-linking, indicating that cross-linking of FcgRII alone
does not result in calcium influx (39). An inhibitory role
for FcgRII is revealed when wild-type and FcgRII2/2
macrophages are compared for calcium influx responses
(Fig. 6 A). Cross-linking of both FcgRII and III receptors
on wild-type macrophages generates a rapid [Ca21] influx
of 60 nM, whereas in the absence of coexpressed FcgRII,
2.4G2 cross-linking of FcgRIII alone generates a larger
[Ca21] influx of 110 nM. This enhanced calcium influx is
likely the result of the stimulated g chain activation pathway
unbridled from the inhibitory effect of FcgRII-mediated
SHIP recruitment. To further assess the functional conse-
quences of FcgRII deficiency, wild-type and FcgRII2/2
macrophages were compared for phagocytic activity (Fig. 6
B). It has been previously demonstrated that antibody-
mediated macrophage phagocytosis requires g chain expres-
sion both in vivo and in vitro (11, 36). In the current study,
the lack of FcgRII expression is associated with enhanced
phagocytosis of IgG2b-coated RBCs. These in vitro studies
are consistent with FcgRII functioning as a general regula-
tor of ITAM-mediated activation in inflammatory cells and
is likely to account for the enhanced inflammation observed
in the FcgRII2/2 mice challenged with ICs.
Figure 5. Enhanced cytokine and chemokine production in IC-stimu-
lated FcgRII2/2 mice. (A) TNF-a production in wild-type (WT) and
FcgRII2/2 mice. ELISA measurements of BAL aliquots. (B) Chemotactic
activity of wild-type and FcgRII2/2 BAL. Migration of wild-type neu-
trophils elicited by dilutions of BAL fluids. Chemotactic responses are ex-
pressed as the percentage of the total neutrophils loaded into the upper
chamber which migrated into the lower BAL fluid–containing chamber.
Mice received OVA (black bars) or PBS (white bars) intravenously, fol-
lowed by 30 mg anti-OVA intratracheally. Experimental groups included
four to seven mice per group. Data are presented as mean 6 SEM. The P
values for IC-stimulated TNF and chemokine production responses were
0.02 and 0.005, FcgRII2/2 vs. wild-type, respectively. Statistical analysis
was performed with an unpaired two-tailed Student’s t test.
Figure 6. Enhanced FcgR-triggered responses of FcgRII2/2 macro-
phages. (A) Phagocytosis of IgG2b-coated RBCs is enhanced in FcgRII2/2:
phagocytic index is expressed as the number of RBCs ingested by 500
representative macrophages. (B) Enhanced calcium flux responses upon
FcR ligation in FcgRII2/2 mice. Peritoneal macrophages were preincu-
bated with mAb 2.4G2 before stimulation with the secondary antibody,
goat anti–rat IgG mAb. Relative fluorescence indicative of intracellular
Ca21 is shown for wild-type (WT) and FcgRII2/2 mice.184 Activation and Inhibitory Fc Receptors In Vivo
Discussion
Although the inflammatory cascade induced by ICs ulti-
mately involves a complex interplay of cells and the molec-
ular mediators of inflammation, the initiation of the IgG-
triggered cascade has been found to be singularly dependent
on engagement and activation of the ITAM-containing g
chain–associated Fc receptors (1). Gene-targeted mice that
lack these receptors are protected from the pathological
consequences of cytotoxic IgG and IgG-containing soluble
ICs (3–5, 36, 37). The present study adds to prior studies in
highlighting the requirement for g chain activation in IC-
triggered inflammatory responses in the lung, kidney, and
skin. These data argue for a general model of IC-mediated
injury, regardless of tissue site, in which the regulation of
the FcgR g activation pathway(s) rather than complement
activation is critical to the initiation of the inflammatory
cascade.
IC injury may result from activation of resident tissue in-
flammatory cells and/or the recruitment of circulating
monocytes or neutrophils to sites of deposition. In the skin,
resident FcgR-bearing mast cells are necessary for initiation
of the IC-triggered Arthus reaction (40). The FcgR-bear-
ing resident cell in the lung responsible for initiating the in-
flammatory response is likely to be the alveolar macro-
phage. These cells elaborate several inflammatory mediators
critical to IC-induced alveolitis, including the cytokines
IL-1, TNF-a, IL-6 (21–26), and several chemokines, in-
cluding MIP-1 and C-X-C cytokines (28–33; for a review,
see reference 34). The production of these inflammatory
mediators during the IC alveolitis response is enhanced in
FcgRII2/2 mice, including the cytokine TNF-a as well as
chemokines. This is consistent with the hypothesis that IC
stimulation of FcgR-bearing tissue resident cells, like the
alveolar macrophage, regulates the initiation of the inflam-
matory response. The balance of FcgR g stimulatory and
FcgRII inhibitory inputs likely determines the cellular
threshold of IC-stimulated activation of these resident cells.
The absence of SHIP-mediated inhibitory effects on early g
chain signaling events in FcgRII-deficient macrophages is
manifested as increased calcium influxes upon cross-linking
of FcgRIII. This unbridling of FcgRIII results in enhanced
phagocytosis of IgG2b-opsonized RBCs by FcgRII2/2
macrophages.
These results demonstrate the regulatory role of the acti-
vating and inhibitory Fcg receptors in initiating IC alveoli-
tis, challenging the viewpoint that the relative contribu-
tions of complement and FcgR pathways is dependent on
tissue site (38). These data suggest instead that the shared
mechanisms of IC-induced injury in the skin, lung, and
kidney are likely indicative of a common pathway of au-
toantibody pathogenesis at other tissue sites. Two potential
therapeutic strategies are suggested by these data. Upregu-
lation of the FcgRII inhibitory pathway or downregulation
of the FcgR g pathway would reduce IC-triggered inflam-
matory responses. The ratio of expression of the activating
FcgRIII and inhibitory FcgRII receptors is likely to deter-
mine the IC concentration threshold required to trigger ef-
fector cell activation. The identification of cytokines or
agents that raise the ratio of surface expression of FcgRII/
FcgRIII would likely raise the IC threshold required for
cellular activation, potentially providing a novel class of an-
tiinflammatory therapeutics.
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